{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06328738",
            "orgStudyIdInfo": {
                "id": "ELVN-002-003"
            },
            "organization": {
                "fullName": "Enliven Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer",
            "officialTitle": "A Phase 1a/1b Study of ELVN-002 Combined With Trastuzumab in Advanced Stage HER2+ Solid Tumors, and ELVN-002 Combined With Trastuzumab and Chemotherapy in Advanced Stage HER2+ Colorectal Cancer and Breast Cancer",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "elvn-with-trastuzumab-chemotherapy-in-solid-tumors-colorectal-and-breast-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-05-30",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-07",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-10",
            "studyFirstSubmitQcDate": "2024-03-18",
            "studyFirstPostDateStruct": {
                "date": "2024-03-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-18",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Enliven Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive tumors and in combination with trastuzumab, and chemotherapy in participants with advanced-stage HER2-positive colorectal cancer and breast cancer.",
            "detailedDescription": "Parts 1 and 3 of this study are designed to evaluate preliminary safety, tolerability, and pharmacokinetics (PK) of ELVN-002 in combination with trastuzumab in participants with advanced stage HER2 positive solid tumors. In addition, Part 3 will evaluate the preliminary efficacy of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive solid tumors.\n\nPart 2 of this study will evaluate the preliminary safety, tolerability, and PK of ELVN-002 in combination with trastuzumab and chemotherapy; capecitabine and oxaliplatin(CAPEOX) or 5-fluorouracil (5-FU), leucovorin (LCV) and oxaliplatin (mFOLFOX6) in participants with advanced stage HER2 positive colorectal cancer, or eribulin, capecitabine, or paclitaxel in participants with advanced-stage HER2-positive breast cancer.\n\nIn part 4, the preliminary safety, tolerability, PK, and efficacy of ELVN-002 in combination with trastuzumab and CAPEOX or mFOLFOX6 will be evaluated in participants with HER2-positive colorectal cancer."
        },
        "conditionsModule": {
            "conditions": [
                "HER2-positive Breast Cancer",
                "HER2-positive Gastric Cancer",
                "HER2 Positive Solid Tumors",
                "HER2 Amplification",
                "Colorectal Cancer"
            ],
            "keywords": [
                "ELVN-002",
                "HER2 positive Colorectal Cancer",
                "HER2 overexpression",
                "HER2"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "Phase 1a will be a dose escalation of ELVN-002 in combination with fixed doses of trastuzumab or trastuzumab + chemotherapy according to the Bayesian Optimal Interval Design model. Phase 1b will be a dose expansion at one or more doses of ELVN-002.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 255,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Part 1: ELVN-002 + trastuzumab dose escalation",
                    "type": "EXPERIMENTAL",
                    "description": "ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.",
                    "interventionNames": [
                        "Drug: ELVN-002",
                        "Drug: Trastuzumab"
                    ]
                },
                {
                    "label": "Part 2A: ELVN-002 + trastuzumab + CAPEOX dose escalation in colorectal cancer",
                    "type": "EXPERIMENTAL",
                    "description": "ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Capecitabine will be administered orally twice daily at 1000 mg/m2 on days 1 - 14 of a 21-day cycle. Oxaliplatin will be administered intravenously at 130 mg/m2 on day 1 of a 21-day cycle.",
                    "interventionNames": [
                        "Drug: ELVN-002",
                        "Drug: Trastuzumab",
                        "Drug: Oxaliplatin",
                        "Drug: Capecitabine"
                    ]
                },
                {
                    "label": "Part 2B: ELVN-002 + trastuzumab + mFOLFOX6 dose escalation in colorectal cancer",
                    "type": "EXPERIMENTAL",
                    "description": "ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered intravenously in 14-day cycles, 4 mg/kg IV cycle 1, day 2 followed by 2 mg/kg IV cycle 1, day 8, 4mg/kg IV cycle 1, day 15, and then one dose of 4 mg/kg every 14 days. Fluorouracil (5-FU) will be administered intravenously as a 400 mg/m2 IV bolus on days 1 and 15 followed by 2400 mg/m2 over 46-48 hours of continuous infusion on days 1-3 and days 15-17 of a 28-day cycle. Leucovorin will be administered intravenously at 400 mg/m2 concurrently with oxaliplatin on days 1 and 15 of a 28-day cycle. Oxaliplatin will be administered intravenously at 85 mg/m2 IV on day 1 and 15 of a 28-day cycle.",
                    "interventionNames": [
                        "Drug: ELVN-002",
                        "Drug: Trastuzumab",
                        "Drug: 5-Fluorouracil",
                        "Drug: Oxaliplatin",
                        "Drug: Leucovorin"
                    ]
                },
                {
                    "label": "Part 2C: ELVN-002 + trastuzumab + capecitabine dose escalation in breast cancer",
                    "type": "EXPERIMENTAL",
                    "description": "ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Capecitabine will be administered orally twice daily at 1250 mg/m2 on days 1 - 14 of a 21-day cycle.",
                    "interventionNames": [
                        "Drug: ELVN-002",
                        "Drug: Trastuzumab",
                        "Drug: Capecitabine"
                    ]
                },
                {
                    "label": "Part 2D: ELVN-002 + trastuzumab + paclitaxel dose escalation in breast cancer",
                    "type": "EXPERIMENTAL",
                    "description": "ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Paclitaxel will be administered intravenously at 80 mg/m2 on days 1, 8, and 15 of a 21-day cycle.",
                    "interventionNames": [
                        "Drug: ELVN-002",
                        "Drug: Trastuzumab",
                        "Drug: paclitaxel"
                    ]
                },
                {
                    "label": "Part 2E: ELVN-002 + trastuzumab + eribulin dose escalation in breast cancer",
                    "type": "EXPERIMENTAL",
                    "description": "ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Eribulin will be administered intravenously at 1.4 mg/m2 on days 1 and 8 of a 21-day cycle.",
                    "interventionNames": [
                        "Drug: ELVN-002",
                        "Drug: Trastuzumab",
                        "Drug: Eribulin"
                    ]
                },
                {
                    "label": "Part 3A: ELVN-002 + trastuzumab dose expansion in colorectal cancer",
                    "type": "EXPERIMENTAL",
                    "description": "ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+",
                    "interventionNames": [
                        "Drug: ELVN-002",
                        "Drug: Trastuzumab"
                    ]
                },
                {
                    "label": "Part 3B: ELVN-002 + trastuzumab dose expansion in breast cancer",
                    "type": "EXPERIMENTAL",
                    "description": "ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.",
                    "interventionNames": [
                        "Drug: ELVN-002",
                        "Drug: Trastuzumab"
                    ]
                },
                {
                    "label": "Part 3C: ELVN-002 + trastuzumab dose expansion in other solid tumor type 1",
                    "type": "EXPERIMENTAL",
                    "description": "ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.",
                    "interventionNames": [
                        "Drug: ELVN-002",
                        "Drug: Trastuzumab"
                    ]
                },
                {
                    "label": "Part 3D: ELVN-002 + trastuzumab dose expansion in other solid tumor type 2",
                    "type": "EXPERIMENTAL",
                    "description": "ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.",
                    "interventionNames": [
                        "Drug: ELVN-002",
                        "Drug: Trastuzumab"
                    ]
                },
                {
                    "label": "Part 3E: ELVN-002 + trastuzumab dose expansion in other solid tumor type 3",
                    "type": "EXPERIMENTAL",
                    "description": "ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+.",
                    "interventionNames": [
                        "Drug: ELVN-002",
                        "Drug: Trastuzumab"
                    ]
                },
                {
                    "label": "Part 4A: ELVN-002 + trastuzumab + CAPEOX dose expansion in colorectal cancer",
                    "type": "EXPERIMENTAL",
                    "description": "ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered IV (intravenously) in 21-day cycles, at 8mg/kg on cycle 1 day 2 followed by a dose of 6mg/kg on day 1 of cycles 2+. Capecitabine will be administered orally twice daily at 1000 mg/m2 on Days 1 - 14 of a 21-day cycle. Oxaliplatin: will be administered intravenously at 130 mg/m2 on Day 1 of a 21-day cycle.",
                    "interventionNames": [
                        "Drug: ELVN-002",
                        "Drug: Trastuzumab",
                        "Drug: Oxaliplatin",
                        "Drug: Capecitabine"
                    ]
                },
                {
                    "label": "Part 4B: ELVN-002 + trastuzumab + mFOLFOX6 dose expansion in colorectal cancer",
                    "type": "EXPERIMENTAL",
                    "description": "ELVN-002 will be administered by mouth (orally) once or twice a day from cycle 1 day 1 onwards. Trastuzumab will be administered intravenously in 14-day cycles, 4 mg/kg IV cycle 1, day 2 followed by 2 mg/kg IV cycle 1, day 8, 4mg/kg IV cycle 1, day 15, and then one dose of 4 mg/kg every 14 days. Fluorouracil (5-FU) will be administered intravenously as a 400 mg/m2 IV bolus on days 1 and 15 followed by 2400 mg/m2 over 46-48 hours of continuous infusion on days 1-3 and days 15-17 of a 28-day cycle. Leucovorin will be administered intravenously at 400 mg/m2 concurrently with oxaliplatin on days 1 and 15 of a 28-day cycle. Oxaliplatin will be administered intravenously at 85 mg/m2 IV on days 1 and 15 of a 28-day cycle.",
                    "interventionNames": [
                        "Drug: ELVN-002",
                        "Drug: Trastuzumab",
                        "Drug: 5-Fluorouracil",
                        "Drug: Oxaliplatin",
                        "Drug: Leucovorin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "ELVN-002",
                    "description": "capsule",
                    "armGroupLabels": [
                        "Part 1: ELVN-002 + trastuzumab dose escalation",
                        "Part 2A: ELVN-002 + trastuzumab + CAPEOX dose escalation in colorectal cancer",
                        "Part 2B: ELVN-002 + trastuzumab + mFOLFOX6 dose escalation in colorectal cancer",
                        "Part 2C: ELVN-002 + trastuzumab + capecitabine dose escalation in breast cancer",
                        "Part 2D: ELVN-002 + trastuzumab + paclitaxel dose escalation in breast cancer",
                        "Part 2E: ELVN-002 + trastuzumab + eribulin dose escalation in breast cancer",
                        "Part 3A: ELVN-002 + trastuzumab dose expansion in colorectal cancer",
                        "Part 3B: ELVN-002 + trastuzumab dose expansion in breast cancer",
                        "Part 3C: ELVN-002 + trastuzumab dose expansion in other solid tumor type 1",
                        "Part 3D: ELVN-002 + trastuzumab dose expansion in other solid tumor type 2",
                        "Part 3E: ELVN-002 + trastuzumab dose expansion in other solid tumor type 3",
                        "Part 4A: ELVN-002 + trastuzumab + CAPEOX dose expansion in colorectal cancer",
                        "Part 4B: ELVN-002 + trastuzumab + mFOLFOX6 dose expansion in colorectal cancer"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Trastuzumab",
                    "description": "intravenous",
                    "armGroupLabels": [
                        "Part 1: ELVN-002 + trastuzumab dose escalation",
                        "Part 2A: ELVN-002 + trastuzumab + CAPEOX dose escalation in colorectal cancer",
                        "Part 2B: ELVN-002 + trastuzumab + mFOLFOX6 dose escalation in colorectal cancer",
                        "Part 2C: ELVN-002 + trastuzumab + capecitabine dose escalation in breast cancer",
                        "Part 2D: ELVN-002 + trastuzumab + paclitaxel dose escalation in breast cancer",
                        "Part 2E: ELVN-002 + trastuzumab + eribulin dose escalation in breast cancer",
                        "Part 3A: ELVN-002 + trastuzumab dose expansion in colorectal cancer",
                        "Part 3B: ELVN-002 + trastuzumab dose expansion in breast cancer",
                        "Part 3C: ELVN-002 + trastuzumab dose expansion in other solid tumor type 1",
                        "Part 3D: ELVN-002 + trastuzumab dose expansion in other solid tumor type 2",
                        "Part 3E: ELVN-002 + trastuzumab dose expansion in other solid tumor type 3",
                        "Part 4A: ELVN-002 + trastuzumab + CAPEOX dose expansion in colorectal cancer",
                        "Part 4B: ELVN-002 + trastuzumab + mFOLFOX6 dose expansion in colorectal cancer"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "5-Fluorouracil",
                    "description": "intravenous",
                    "armGroupLabels": [
                        "Part 2B: ELVN-002 + trastuzumab + mFOLFOX6 dose escalation in colorectal cancer",
                        "Part 4B: ELVN-002 + trastuzumab + mFOLFOX6 dose expansion in colorectal cancer"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Oxaliplatin",
                    "description": "intravenous",
                    "armGroupLabels": [
                        "Part 2A: ELVN-002 + trastuzumab + CAPEOX dose escalation in colorectal cancer",
                        "Part 2B: ELVN-002 + trastuzumab + mFOLFOX6 dose escalation in colorectal cancer",
                        "Part 4A: ELVN-002 + trastuzumab + CAPEOX dose expansion in colorectal cancer",
                        "Part 4B: ELVN-002 + trastuzumab + mFOLFOX6 dose expansion in colorectal cancer"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Capecitabine",
                    "description": "capsule",
                    "armGroupLabels": [
                        "Part 2A: ELVN-002 + trastuzumab + CAPEOX dose escalation in colorectal cancer",
                        "Part 2C: ELVN-002 + trastuzumab + capecitabine dose escalation in breast cancer",
                        "Part 4A: ELVN-002 + trastuzumab + CAPEOX dose expansion in colorectal cancer"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Eribulin",
                    "description": "intravenous",
                    "armGroupLabels": [
                        "Part 2E: ELVN-002 + trastuzumab + eribulin dose escalation in breast cancer"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "paclitaxel",
                    "description": "intravenous",
                    "armGroupLabels": [
                        "Part 2D: ELVN-002 + trastuzumab + paclitaxel dose escalation in breast cancer"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Leucovorin",
                    "description": "intravenous",
                    "armGroupLabels": [
                        "Part 2B: ELVN-002 + trastuzumab + mFOLFOX6 dose escalation in colorectal cancer",
                        "Part 4B: ELVN-002 + trastuzumab + mFOLFOX6 dose expansion in colorectal cancer"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of dose limiting toxicities (DLTs; Phase 1a only)",
                    "description": "DLTs will be used to support that the recommended doses for expansion are \\</= maximum tolerated dose (MTD)",
                    "timeFrame": "21 days"
                },
                {
                    "measure": "Incidence of adverse events (AEs)",
                    "description": "AEs will be used to support that the recommended doses for expansion are likely to be tolerable",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Incidence of laboratory abnormalities",
                    "description": "Clinically significant laboratory abnormalities will be used to support that the recommended doses for expansion are likely to be tolerable",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Incidence of electrocardiogram abnormalities",
                    "description": "Clinically significant electrocardiogram abnormalities will be used to support that the recommended doses for expansion are likely to be tolerable",
                    "timeFrame": "24 months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "PK parameter of area under the curve of ELVN-002 (Phase 1a only)",
                    "description": "The concentration of ELVN-002 measured in the blood over 24 hours at steady state",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "PK parameter of maximum concentration of ELVN-002 (Phase 1a only)",
                    "description": "The maximum concentration of ELVN-002 measured in the blood at any time point at steady state",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "PK parameter of minimum concentration of ELVN-002 (Phase 1a only)",
                    "description": "The minimum concentration of ELVN-002 measured in the blood at any time point at steady",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "PK parameter of terminal half life of ELVN-002 (Phase 1a only)",
                    "description": "The half life of ELVN-002 calculated from the concentration of ELVN-002 measured in blood",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Confirmed objective response rate (ORR)",
                    "description": "For patients with measurable disease at baseline, confirmed response as assessed by investigator per RECIST v1.1",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Duration of response (DOR; Phase 1b only)",
                    "description": "The time from the first response to progression or death per RECIST v1.1",
                    "timeFrame": "24 months"
                },
                {
                    "measure": "Brain metastases response (Phase 1b only)",
                    "description": "For patients with measurable brain metastases at baseline, the percent of patients who have a confirmed response per RECIST v1.1",
                    "timeFrame": "24 months"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Pathologically or histologically documented solid tumor.\n* Locally advanced or relapsed/refractory disease or unresectable metastatic disease.\n* HER2-positive disease based on the following local testing:\n\n  * Colorectal cancer: IHC3+, IHC2+/ISH+, NGS amplification by tissue (no RAS or BRAF mutation allowed)\n  * Breast cancer: IHC3+ or IHC2+/ISH+ by tissue\n  * Gastric cancer: IHC3+ or IHC2+/ISH+ by tissue\n  * Other cancers: IHC3+, IHC2+/ISH+, NGS amplification by tissue or ctDNA\n* Prior therapies for Part 1 (Dose Escalation ELVN-002 + trastuzumab):\n\n  * Colorectal cancer: treated with prior fluoropyrimidine, oxaliplatin, irinotecan-based regimens, anti-epidermal growth factor receptor (EGFR) treatment (if clinically indicated), anti-vascular endothelial growth factor (VEGF) treatment (if clinically indicated), and an anti-programmed death ligand 1 (PD-(L)-1) treatment (if the tumor is microsatellite instability (MSI)-high/deficient mismatch repair (dMMR)\n  * Breast cancer: treated with prior taxane, pertuzumab, trastuzumab, and fam-trastuzumab deruxtecan (T-DXd) if available and appropriate based on local standard of care and investigator's assessment\n  * Gastric cancer: treated with trastuzumab/platinum fluorouracil containing regimen and T-DXd.\n  * Other cancers: progressed during or after \u2265 1 prior line of systemic therapy for locally advanced unresectable or metastatic disease\n  * Prior HER2 targeted therapy is allowed\n* Prior therapies for Part 2 (Phase 1a Dose Escalation ELVN-002 + trastuzumab + chemotherapy):\n\n  * Colorectal cancer: candidate for CAPEOX (capecitabine and oxaliplatin) or mFOLFOX6 (5-FU, LCV and oxaliplatin), and treated, if clinically indicated, with an anti-programmed death ligand 1 (PD-(L)-1) treatment (if the tumor is microsatellite instability (MSI)-high/deficient mismatch repair (dMMR). Prior HER2 targeted therapy is allowed.\n  * Breast cancer: candidate for capecitabine, paclitaxel or eribulin, and treated with prior taxane, pertuzumab, trastuzumab, and T-DXd, if available and appropriate, based on local standard of care and investigator's assessment. No prior HER2 targeted tyrosine kinase inhibitor therapy (antibody-drug conjugates and antibodies are allowed), no prior capecitabine (for the capecitabine cohort), no prior eribulin (for the eribulin cohort), and no taxane as immediate prior therapy (paclitaxel cohort).\n* Prior therapies for Part 3 (Phase 1b Dose Expansion ELVN-002 + trastuzumab):\n\n  * Colorectal cancer: treated with prior fluoropyrimidine, oxaliplatin, irinotecan-based regimens, anti-epidermal growth factor receptor (EGFR) treatment (if clinically indicated), anti-vascular endothelial growth factor (VEGF) treatment (if clinically indicated), and an anti-programmed death ligand 1 (PD-(L)-1) treatment if the tumor is microsatellite instability (MSI)-high/deficient mismatch repair (dMMR). No prior HER2 targeted therapy.\n  * Breast cancer: treated with prior taxane, pertuzumab, trastuzumab, and T-DXd if available and appropriate based on local standard of care and investigator's assessment. No prior HER2 targeted tyrosine kinase inhibitor therapy (antibody-drug conjugates and antibodies are allowed).\n  * Gastric cancer: treated with prior trastuzumab/platinum fluorouracil containing regimen and T-DXd. No prior HER2 targeted therapy.\n  * Other cancers: Progressed during or after \u2265 1 prior line of systemic therapy for locally advanced unresectable or metastatic disease. No prior HER2 targeted therapy.\n* Prior therapies for Part 4 (Phase 1b Dose Expansion ELVN-002 + trastuzumab + chemotherapy):\n\n  \\* Colorectal cancer: candidate for CAPEOX or mFOLFOX6 and not a candidate for first-line anti-programmed death ligand 1 (PD-(L)-1) treatment (if the tumor is microsatellite instability (MSI)-high/deficient mismatch repair (dMMR). No prior therapy for metastatic disease (1 cycle of mFOLFOX6 or 1 cycle of CAPEOX allowed). No prior HER2 targeted therapy.\n* At least 1 measurable lesion based on RECIST v 1.1 within 6 weeks before the first dose of ELVN-002 (Part 3 and Part 4 only; Phase 1b Dose Expansion cohorts)\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n* Adequate hematological, hepatic, renal, and cardiac function\n\nExclusion Criteria:\n\n* Treatment with anticancer therapy within a specific time before the first dose:\n\n  * Chemotherapy (including ADC) \u2264 3 weeks\n  * Immunotherapy \u2264 4 weeks\n  * Hormonal therapy \u2264 2 weeks\n  * TKI \u2264 2 weeks\n  * Any experimental therapy \u2264 3 weeks or 5 half-lives, whichever is longer\n  * Radiotherapy-wide therapy \u2264 3 weeks\n  * Radiotherapy limited field (including stereotactic brain) \u2264 2 weeks\n  * Antibody \u2264 3 weeks\n* Any brain lesion requiring immediate local therapy\n* Ongoing use of corticosteroids for central nervous system (CNS) symptoms at a dose of \\> 2 mg daily of dexamethasone (or equivalent)\n* Leptomeningeal disease\n* Uncontrolled seizures\n* Participants for any chemotherapy cohort: ongoing Grade 2 or higher neuropathy of any cause\n* Inability to swallow pills or any significant gastrointestinal disease that would preclude adequate oral absorption of medications.\n* Ongoing adverse effects from prior treatment \\> CTCAE Grade 1 except for Grade 2 alopecia\n* Corrected QT interval (QTc) of \\>470 milliseconds (ms) for females or \\>450 ms for males",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Helen L Collins, MD",
                    "role": "CONTACT",
                    "phone": "7077993272",
                    "email": "helen.collins@enliventherapeutics.com"
                }
            ],
            "locations": [
                {
                    "facility": "BRCR Medical Center Inc.",
                    "status": "RECRUITING",
                    "city": "Plantation",
                    "state": "Florida",
                    "zip": "33322",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Harshad V. Amin, M.D.",
                            "role": "CONTACT"
                        }
                    ],
                    "geoPoint": {
                        "lat": 26.13421,
                        "lon": -80.23184
                    }
                },
                {
                    "facility": "NEXT Virginia",
                    "status": "RECRUITING",
                    "city": "Fairfax",
                    "state": "Virginia",
                    "zip": "22031",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alexander Spira, MD",
                            "role": "CONTACT",
                            "phone": "703-636-1473"
                        }
                    ],
                    "geoPoint": {
                        "lat": 38.84622,
                        "lon": -77.30637
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000001943",
                    "term": "Breast Neoplasms"
                },
                {
                    "id": "D000015179",
                    "term": "Colorectal Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000001941",
                    "term": "Breast Diseases"
                },
                {
                    "id": "D000012871",
                    "term": "Skin Diseases"
                },
                {
                    "id": "D000007414",
                    "term": "Intestinal Neoplasms"
                },
                {
                    "id": "D000005770",
                    "term": "Gastrointestinal Neoplasms"
                },
                {
                    "id": "D000004067",
                    "term": "Digestive System Neoplasms"
                },
                {
                    "id": "D000004066",
                    "term": "Digestive System Diseases"
                },
                {
                    "id": "D000005767",
                    "term": "Gastrointestinal Diseases"
                },
                {
                    "id": "D000003108",
                    "term": "Colonic Diseases"
                },
                {
                    "id": "D000007410",
                    "term": "Intestinal Diseases"
                },
                {
                    "id": "D000012002",
                    "term": "Rectal Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M5220",
                    "name": "Breast Neoplasms",
                    "asFound": "Breast Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M16064",
                    "name": "Stomach Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M17890",
                    "name": "Colorectal Neoplasms",
                    "asFound": "Colorectal Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5218",
                    "name": "Breast Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15674",
                    "name": "Skin Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10448",
                    "name": "Intestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7256",
                    "name": "Digestive System Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M8886",
                    "name": "Gastrointestinal Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M7255",
                    "name": "Digestive System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8883",
                    "name": "Gastrointestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M6336",
                    "name": "Colonic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10444",
                    "name": "Intestinal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14844",
                    "name": "Rectal Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T5486",
                    "name": "Stomach Cancer",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC17",
                    "name": "Skin and Connective Tissue Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC06",
                    "name": "Digestive System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000002955",
                    "term": "Leucovorin"
                },
                {
                    "id": "D000017239",
                    "term": "Paclitaxel"
                },
                {
                    "id": "D000069287",
                    "term": "Capecitabine"
                },
                {
                    "id": "D000077150",
                    "term": "Oxaliplatin"
                },
                {
                    "id": "D000005472",
                    "term": "Fluorouracil"
                },
                {
                    "id": "D000068878",
                    "term": "Trastuzumab"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000972",
                    "term": "Antineoplastic Agents, Phytogenic"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000050257",
                    "term": "Tubulin Modulators"
                },
                {
                    "id": "D000050256",
                    "term": "Antimitotic Agents"
                },
                {
                    "id": "D000050258",
                    "term": "Mitosis Modulators"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000000964",
                    "term": "Antimetabolites, Antineoplastic"
                },
                {
                    "id": "D000000963",
                    "term": "Antimetabolites"
                },
                {
                    "id": "D000007166",
                    "term": "Immunosuppressive Agents"
                },
                {
                    "id": "D000007155",
                    "term": "Immunologic Factors"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000074322",
                    "term": "Antineoplastic Agents, Immunological"
                },
                {
                    "id": "D000000931",
                    "term": "Antidotes"
                },
                {
                    "id": "D000020011",
                    "term": "Protective Agents"
                },
                {
                    "id": "D000014803",
                    "term": "Vitamin B Complex"
                },
                {
                    "id": "D000014815",
                    "term": "Vitamins"
                },
                {
                    "id": "D000018977",
                    "term": "Micronutrients"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M19537",
                    "name": "Paclitaxel",
                    "asFound": "Sessions",
                    "relevance": "HIGH"
                },
                {
                    "id": "M377",
                    "name": "Capecitabine",
                    "asFound": "200",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1674",
                    "name": "Oxaliplatin",
                    "asFound": "Min",
                    "relevance": "HIGH"
                },
                {
                    "id": "M325",
                    "name": "Trastuzumab",
                    "asFound": "Follow-up",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8600",
                    "name": "Fluorouracil",
                    "asFound": "According",
                    "relevance": "HIGH"
                },
                {
                    "id": "M231",
                    "name": "Albumin-Bound Paclitaxel",
                    "relevance": "LOW"
                },
                {
                    "id": "M6191",
                    "name": "Leucovorin",
                    "asFound": "Sodium",
                    "relevance": "HIGH"
                },
                {
                    "id": "M26197",
                    "name": "Tubulin Modulators",
                    "relevance": "LOW"
                },
                {
                    "id": "M26196",
                    "name": "Antimitotic Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M4281",
                    "name": "Antimetabolites",
                    "relevance": "LOW"
                },
                {
                    "id": "M10212",
                    "name": "Immunosuppressive Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M10201",
                    "name": "Immunologic Factors",
                    "relevance": "LOW"
                },
                {
                    "id": "M1346",
                    "name": "Antineoplastic Agents, Immunological",
                    "relevance": "LOW"
                },
                {
                    "id": "M4250",
                    "name": "Antidotes",
                    "relevance": "LOW"
                },
                {
                    "id": "M21869",
                    "name": "Protective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M17558",
                    "name": "Vitamins",
                    "relevance": "LOW"
                },
                {
                    "id": "M17546",
                    "name": "Vitamin B Complex",
                    "relevance": "LOW"
                },
                {
                    "id": "M8618",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "M21009",
                    "name": "Micronutrients",
                    "relevance": "LOW"
                },
                {
                    "id": "M16885",
                    "name": "Trace Elements",
                    "relevance": "LOW"
                },
                {
                    "id": "T446",
                    "name": "Folic Acid",
                    "relevance": "LOW"
                },
                {
                    "id": "T448",
                    "name": "Folate",
                    "relevance": "LOW"
                },
                {
                    "id": "T475",
                    "name": "Vitamin B9",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "Micro",
                    "name": "Micronutrients"
                },
                {
                    "abbrev": "Hemat",
                    "name": "Hematinics"
                },
                {
                    "abbrev": "Vi",
                    "name": "Vitamins"
                }
            ]
        }
    },
    "hasResults": false
}